Clinical Efficacy of Topical Tacrolimus on Conjunctival Hyperemia Caused by Prostaglandin Analogues
CONCLUSION: Tacrolimus ophthalmic solution can relieve conjunctival hyperemia, improve ocular surface conditions, and reduce discomfort caused by prostaglandin analogues.PMID:36276850 | PMC:PMC9586722 | DOI:10.1155/2022/3700720 (Source: Evidence-based Complementary and Alternative Medicine)
Source: Evidence-based Complementary and Alternative Medicine - October 24, 2022 Category: Complementary Medicine Authors: Jing Yang Yiyu Shi Haibo Chen Source Type: research
Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma
Glaucoma is the main cause of irreversible visual loss worldwide, and comprises a group of progressive, age-related, and chronic optic neuropathies. Prostaglandin analogs are considered a first-line treatment in the management of glaucoma and have the best efficacy in reducing intraocular pressure. When comparing these therapeutic agents between them, long-term therapy with 0.03% bimatoprost is the most effective followed by treatment with 0.005% latanoprost and 0.004% travoprost. The prevalence of adverse events is lower for latanoprost than for other prostaglandin analogs. However, some patients do not respond to the tre...
Source: Frontiers in Pharmacology - October 12, 2022 Category: Drugs & Pharmacology Source Type: research
HSD8 Real-World Patient Persistence: A Comparison of Prostaglandin Analogs Used for the Treatment of Open-Angle Glaucoma or Ocular Hypertension
This study aims to compare persistence on latanoprostene bunod, latanoprost, bimatoprost, travoprost, and Beta Blockers, within a 12-month analysis period. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: C Laforty, S Feener, P Grover, A Sharma, M Barbeau Source Type: research
Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment
CONCLUSION: PF tafluprost/timolol FC therapy provided statistically and clinically significant IOP reductions from Week 4 over the total 6-month period, in patients with OAG/OHT, regardless of the type of prior PGA or beta-blocker monotherapy used. Conjunctival hyperemia severity and CFS decreased significantly in prior bimatoprost and preserved latanoprost users, respectively.CLINICAL STUDY NUMBER: European Union electronic Register of Post-Authorization Studies (EU PAS) register number: EUPAS22204.PMID:35524840 | DOI:10.1007/s12325-022-02166-6 (Source: Adv Data)
Source: Adv Data - May 7, 2022 Category: Epidemiology Authors: Francesco Oddone James Kirwan Fernando Lopez-Lopez Marina Zimina Claudia Fassari G ábor Holló VISIONARY Study Group Source Type: research
Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment
CONCLUSION: PF tafluprost/timolol FC therapy provided statistically and clinically significant IOP reductions from Week 4 over the total 6-month period, in patients with OAG/OHT, regardless of the type of prior PGA or beta-blocker monotherapy used. Conjunctival hyperemia severity and CFS decreased significantly in prior bimatoprost and preserved latanoprost users, respectively.CLINICAL STUDY NUMBER: European Union electronic Register of Post-Authorization Studies (EU PAS) register number: EUPAS22204.PMID:35524840 | DOI:10.1007/s12325-022-02166-6 (Source: Adv Data)
Source: Adv Data - May 7, 2022 Category: Epidemiology Authors: Francesco Oddone James Kirwan Fernando Lopez-Lopez Marina Zimina Claudia Fassari G ábor Holló VISIONARY Study Group Source Type: research
Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment
ConclusionPF tafluprost/timolol FC therapy provided statistically and clinically significant IOP reductions from Week 4 over the total 6-month period, in patients with OAG/OHT, regardless of the type of prior PGA or beta-blocker monotherapy used. Conjunctival hyperemia severity and CFS decreased significantly in prior bimatoprost and preserved latanoprost users, respectively.Clinical Study NumberEuropean Union electronic Register of Post-Authorization Studies (EU PAS) register number: EUPAS22204. (Source: Advances in Therapy)
Source: Advances in Therapy - May 7, 2022 Category: Drugs & Pharmacology Source Type: research
Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
Conclusion
LBN was significantly more effective than the PGA unoprostone and most of the beta-blockers. Compared with the most widely used PGAs, LBN numerically outperformed latanoprost and travoprost and was similar to bimatoprost 0.01%. (Source: British Journal of Ophthalmology)
Source: British Journal of Ophthalmology - April 21, 2022 Category: Opthalmology Authors: Harasymowycz, P., Royer, C., Cui, A. X., Barbeau, M., Jobin-Gervais, K., Mathurin, K., Lachaine, J., Beauchemin, C. Tags: Open access Original articles - Clinical science Source Type: research
Development of IKATP Ion Channel Blockers Targeting Sulfonylurea Resistant Mutant KIR6.2 Based Channels for Treating DEND Syndrome
Conclusion: Our combination of MD and inside-out electrophysiology provides the rationale for drug mediated IKATP inhibition, and will be the basis for 1) screening of additional existing drugs for repurposing to address DEND syndrome, and 2) rationalized medicinal chemistry to improve IKATP inhibitor efficacy and specificity. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - January 14, 2022 Category: Drugs & Pharmacology Source Type: research
Effect of travoprost, latanoprost and bimatoprost PGF2 α treatments on the biomechanical properties of in-vivo rabbit cornea
Exp Eye Res. 2022 Jan 7;215:108920. doi: 10.1016/j.exer.2022.108920. Online ahead of print.ABSTRACTProstaglandin F2α analogues (PGF2α), one of the most commonly prescribed classes of hypotensive agents, could decrease collagen fibril density and remodel the extracellular matrix in cornea. We hypothesized that PGF2α's would induce corneal softening, reduce the accuracy of intraocular pressure (IOP) measurement and lead to uncertainty in the effectiveness of the therapy. We determined the stress-strain behavior of rabbit cornea after PGF2α usage and evaluated the effect of biomechanical changes associated with PGF2α tre...
Source: Experimental Eye Research - January 10, 2022 Category: Opthalmology Authors: JunJie Wang YiPing Zhao AYong Yu Jie Wu ManMan Zhu MuChen Jiang Xuefei Li DaTian Zhu PeiPei Zhang XiaoBo Zheng FangJun Bao Ahmed Elsheikh Source Type: research
Ophthalmic Drugs: In vitro paraoxonase 1 inhibition and molecular docking studies
This study was tested some ophthalmic drugs used to treat the diseases, such as glaucoma and allergic conjunctivitis, mentioned above, travoprost, latanoprost, ketotifen, emedastine, and olopatadine, for their inhibition activities against PON1. These drugs displayed the potent inhibition effect with IC50 values ranging between 14.95 ± 0.15 and 299.60 ± 4.07 μM and KI constants ranging from 9.71 ± 2.63 to 261.50 ± 59.98 μM. Besides, the molecular docking analyses of the competitive inhibitors, travoprost, emedastine, and olopatadine, were performed to understand the binding interactions on the enzyme's binding site. ...
Source: Biotechnology and Applied Biochemistry - November 17, 2021 Category: Biochemistry Authors: B üşra Çalışkan,
Yeliz Demir,
Cüneyt Türkeş Tags: Original Article Source Type: research
Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies
Damage to the optic nerve and the death of associated retinal ganglion cells (RGCs) by elevated intraocular pressure (IOP), also known as glaucoma, is responsible for visual impairment and blindness in millions of people worldwide. The ocular hypertension (OHT) and the deleterious mechanical forces it exerts at the back of the eye, at the level of the optic nerve head/optic disc and lamina cribosa, is the only modifiable risk factor associated with glaucoma that can be treated. The elevated IOP occurs due to the inability of accumulated aqueous humor (AQH) to egress from the anterior chamber of the eye due to occlusion of ...
Source: Frontiers in Pharmacology - September 17, 2021 Category: Drugs & Pharmacology Source Type: research
Proposal of a simple grading system integrating cosmetic and tonometric aspects of prostaglandin-associated periorbitopathy
The distribution of prostaglandin-associated periorbitopathy (PAP) graded using the Shimane University PAP Grading System (SU-PAP) among glaucoma/ocular hypertension subjects using a topical FP or EP2 receptor agonist was reported. A 460 consecutive 460 Japanese subjects (211 men, 249 women; mean age ± standard deviation, 69.9 ± 14.5 years) who had used either a FP agonist (0.005% latanoprost, 0.0015% tafluprost, 0.004% travoprost, 0.03% bimatoprost, or fixed combinations of these) or EP2-agonist (0.002% omidenepag isopropyl) for more than 3 months in at least 1 eye were retrospectively enrolled. Age, sex, pr...
Source: Medicine - August 27, 2021 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
